ERBB2 and cancer: In conclusion, the molecular probe of radionuclide-labeled HER2 affibody can accurately evaluate the expression status of HER2 receptor in epithelial ovarian cancer, which provides favorable conditions for the localization, diagnosis of cancer foci, targeted therapy, and prognosis evaluation.